Printer Friendly

TARGETED GENETICS APPOINTS EXECUTIVE V.P., RESEARCH AND DEVELOPMENT

TARGETED GENETICS APPOINTS EXECUTIVE V.P., RESEARCH AND DEVELOPMENT
 SEATTLE, April 15 /PRNewswire/ -- Targeted Genetics Corp. (TGC) announced today the appointment of Barrie J. Carter, Ph.D., as executive vice president and director, research and development.
 Carter will join TGC from the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health (NIH), where he was Chief of the Laboratory of Molecular and Cellular Biology. Carter has served on a number of editorial boards and NIH review committees, and currently chairs the NIH Biosafety Committee.
 Carter has extensive research experience in molecular biology with special interests in the genetics and biochemistry of the human parvovirus, adeno-associated virus. Part of this research has been directed towards developing viral vectors for gene therapy. Carter is a member of the American Societies of Microbiology, Virology and Biochemistry and Molecular Biology.
 "Barrie Carter brings tremendous expertise and broad knowledge of the gene therapy field to TGC," said H. Stewart Parker, TGC president and chief executive officer. "He is a leading scientist in the area of adeno-associated viruses, which represents important complementary technology to that currently held by TGC. His leadership capabilities will help guide the company at the most exciting time of its history."
 Carter received his Ph.D. in Biochemistry from the University of Otago Medical School, New Zealand.
 Targeted Genetics Corp. is a leader in the development of gene therapy treatments for acquired and inherited diseases. The company is currently beginning its first human clinical trial, a gene therapy- based treatment for HIV infection.
 -0- 4/15/92
 /CONTACT: H. Stewart Parker of Targeted Genetics, 206-623-7612/ CO: Targeted Genetics Corp. ST: Washington IN: MTC SU: PER


LM-TB -- SE005 -- 8650 04/15/92 11:39 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1992
Words:287
Previous Article:GERIATRIC & MEDICAL CENTERS REPORTS RECORD REVENUES AND OPERATING INCOME FOR THE THIRD QUARTER ENDED FEB. 29, 1992
Next Article:COLONIAL INVESTMENT GRADE MUNICIPAL TRUST FIRST QUARTER EARNINGS


Related Articles
TARGETED GENETICS, FRED HUTCHINSON CANCER RESEARCH CENTER RECEIVE APPROVAL TO BEGIN HUMAN GENE THERAPY TRIAL
DONALD L. MURFIN JOINS TARGETED GENETICS BOARD
TARGETED GENETICS CORP.: HIV-KILLING CELLS USED AS EXPERIMENTAL GENE THERAPY
TARGETED GENETICS RECEIVES SBIR GRANT TO DEVELOP LARGE-SCALE MANUFACTURING PROCESS FOR AAV-CFTR VECTORS
TARGETED GENETICS NAMES BRUCE H. DEVENS DIRECTOR OF IMMUNOLOGY
TARGETED GENETICS BEGINS SECOND HUMAN TRIAL OF AAV VECTOR IN NEW GENE THERAPY FOR CYSTIC FIBROSIS
TARGETED GENETICS TO ACQUIRE RGENE THERAPEUTICS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters